|
1.FDA. Guidance for Industry: In vivo bioequivalence studies on population and individual bioequivalence approaches. Center for Drug Evaluation and Research ( CDER), Food and Drug Administration, US Department of Health and Human Services, October, 1997. 2.FDA. Guidance for Industry: Bioavailability and Bioequivalence studies for Nasal Aerosols and Nasal Sprays for Local Action. CDER, FDA, US Department of Health and Human Services, June, 1999. 3.Tsong, "Comparative Statistics for Assessing In-vitro Equivalence Based on Profile measures", Technical report of Orally Inhaled and Nasal Delivery Drug Products Subcommittee of the Advisory Committee for Pharmaceutical Science, 2000. 4.Hyslop T., Hsuan F., Holder D.J., "A small sample confidence interval approach to assess individual bioequivalence", Statistics in Medicine, 19:2885-2897, 2000. 5.EDWIN L. CROW & KUNIO SHIMIZU., Lognormal distributions: theory and applications, MARCEL DEKKER, INC., 1988. 6.Agresti, A., "Categorical data analysis", Wiley, Inc., New York, 1990.
|